Meeting
2023 ASCO Annual Meeting
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.
Authors
Paul B. Chapman
Memorial Sloan Kettering Cancer Center, New York, NY
Paul B. Chapman , Vetri Sudar Jayaprakasam , Margaret K. Callahan , Alexander Noor Shoushtari , Michael A. Postow , Cecilia Lezcano , Jedd D. Wolchok , Subhiksha Nandakumar , Walid Khaled Chatila
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9553)
DOI
10.1200/JCO.2023.41.16_suppl.9553
Abstract #
9553
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
First Author: Paul Lorigan
Poster
2024 ASCO Annual Meeting
The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.
First Author: Zac Coyne
Poster
2023 ASCO Annual Meeting
The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.
First Author: Moh'd M. Khushman
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane